Avantor, Inc. (AVTR)
NYSE · Healthcare · Medical Instruments & Supplies
$15.81+3.06%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $10.7B
- Forward P/E
- 18.0
- 52-week range
- $7.27 – $16.05
- 52-week change
- +8.87%
- EPS (trailing)
- −$0.87
- Analyst rating
- 2.8 Hold
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $6.6B (−3.41%)
- Net income
- −$530M
- Operating margin
- −3.8%
- Diluted EPS
- −$0.78
- Free cash flow
- $495M
From the company’s annual report on SEC EDGAR.
About Avantor, Inc.
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services.
Headquarters: Radnor, United States · 13,500 employees · avantorsciences.com